癌症干细胞的分子特征描述了与预后和免疫景观的相关性,并预测了色细胞瘤和干细胞瘤的风险分层
Lei Li1, Shuangyu Liu2, Zeqi Guo2
1Department of Laboratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing 100730, China.
Bioengineering (Basel, Switzerland)
|March 28, 2025
概括
用基于mRNA表达的干度指数 (mRNAsi) 测量瘤干度,可以预测色细胞瘤和偏瘤 (PPGL) 的转移和预后. 一个新的茎度评分系统有助于对患者进行分层,以定制治疗策略.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 乳红细胞瘤和偏角细胞瘤 (PPGLs) 是一种罕见的神经内分泌瘤,经常出现耐药性高血压.
- 复发和转移的风险需要改进诊断和预后工具.
- 了解瘤生物学,包括茎状,对于预测PPGL行为和指导治疗至关重要.
研究的目的:
- 研究瘤茎在PPGL进展和转移中的作用.
- 开发和验证一种用于预测PPGL预后的新型茎度评分系统.
- 与临床,分子和瘤微环境 (TME) 特征相关联.
主要方法:
- 使用TCGA RNAseq数据和OCLR算法计算基于mRNA表达的干度指数 (mRNAsi).
- 采用加权基因共同表达网络分析 (WGCNA),Cox和LASSO回归来识别与干性相关的枢纽基因.
- 分析了干度,临床参数,分子变化和TME特征之间的关联.
主要成果:
- 转移性PPGLs表现出更高的mRNAsi得分,这表明茎和转移之间存在联系.
- 一种新的干度评分系统有效地将PPGL患者分为高风险和低风险组,具有不同的预后 (AUC=0.908).
- 高风险的PPGL显示出免疫抑制的TME特征,而低风险的PPGL则具有更高的免疫透和新抗原负载,这表明免疫治疗反应差异.
结论:
- 瘤茎是PPGL转移和预后的潜在生物标志物.
- 开发的茎度评分系统为预测患者结果提供了可靠的工具.
- 这种评分系统可以为PPGL患者提供个性化的治疗策略.
相关概念视频
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...


